Abstract
The U.S. Multiple Myeloma Market is a rapidly progressing field that is set to
generate over $3 billion in revenue in the coming years. The market has
witnessed unprecedented growth with the launch of three new drugs. The
dynamics of this market are changing rapidly and the forecast through 2013
highlights the major changes. This study includes patient forecasts, pipeline
analysis and individual product revenue forecasts.
View Cart
